Given the reported 25% discordance for KRAS mutation status between primary and metastatic cancers [84], one could expect a significant number of patients with inaccessible brain metastases harboring wild-type KRAS but whose primary solid biopsies showed KRAS mutations, to be excluded from systemic EGFR treatment, disregarding hence the molecular characteristics of their metastatic lesions. Here, EGFR is linked to metastatic malignant neoplasm.